VIP

Vasoactive Intestinal Peptide

Evidence & Status

  • Preliminary / Experimental
  • Preliminary

At a Glance

A naturally occurring 28-amino-acid neuropeptide. The current record is limited to route-specific human IV pharmacology, inhaled pulmonary-hypertension research, and aviptadil trial-status context; it does not establish broad therapeutic benefit.

Plain English

Researchers study VIP because it is a naturally produced signaling molecule with vascular and immune-system roles. The current human evidence in this record is limited to specific IV and inhaled research settings. Aviptadil is a synthetic VIP formulation with registered COVID-19 trials, but registry entries do not demonstrate clinical efficacy.

Overview

VIP is a naturally occurring 28-amino-acid neuropeptide; aviptadil is a synthetic VIP formulation. The verified record includes review context, human IV pharmacology, and inhaled VIP pulmonary-hypertension research. Aviptadil trial registries provide study-status context only. Evidence is route- and entity-specific and does not establish broad therapeutic efficacy or FDA approval.

Research Summary

VIP/aviptadil remains preliminary. Human evidence is limited and route-specific: IV VIP pharmacology and inhaled pulmonary-hypertension research. Aviptadil COVID-19 registry records establish study status only, not efficacy. No FDA-approved indication or general therapeutic dosing exists.

Research Areas

  • Human IV VIP pharmacology
  • Inhaled VIP pulmonary-hypertension research
  • Aviptadil COVID-19 trial status

Safety & Risks

Serious Risks

  • Route-specific cardiovascular and hemodynamic risks require direct formulation-specific evaluation; long-term human safety and broad clinical efficacy are not established

Reported Side Effects

  • Flushing
  • Transient hypotension (especially IV)
  • Facial warmth
  • Nausea
  • Mild diarrhea
United States
Research only; aviptadil/VIP is not FDA-approved for any indication
United Kingdom
Current authorization status not established in this record
Australia
Current authorization status not established in this record
Canada
Current authorization status not established in this record

Citations & Sources